Asia Pacific Remains Highly Attractive
BMI View : Geographic diversification may be a favourable strategy for multinational pharmaceutical companies, but it is vital that firms recognise both the rewards and the risks present in a market, whether developed or emerging. BMI 's Risk/Rewards Ratings (RRR) tool, which provides a globally comparative and numerically based assessment of a market's attractiveness, was established to address this. In BMI 's Q413 RRRs, the Asia Pacific region scores 53 out of 100, below Western Europe (67), but compares favourably against Americas (51), Central and Eastern Europe (52) and Middle East and Africa (42) regions.
The indicators used to assess the attractiveness of a pharmaceutical market are now visible, improving the transparency of the rating system and enabling the identification of regional or group outperformers across single indicators. A market's RRR score is made up of a sum of the Rewards score (Industry Rewards + Country Rewards) and the Risks score (Industry Risks + Country Risks).
The weight assigned to each subsector (such as Industry Rewards or Industry Risks) shows its influence within the final Rewards or Risks score and the final RRR score. The Rewards component accounts for 65% of the final RRR, while the Risks component accounts for 35%.
|Q114 Asia Pacific Pharmaceutical Risk/Reward Ratings|
|Rewards And Risks Scores|